文献速递特殊人群用药

生理药代动力学模型表征妊娠与非妊娠女性对乙酰氨基酚药代动力学及NAPQI生成

Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women.
PubMed 文献 · Clin Pharmacokinet · 2020-01-01

本研究建立对乙酰氨基酚及其代谢物的生理药代动力学模型,预测妊娠各期药代动力学。结果显示妊娠女性对乙酰氨基酚暴露低于非妊娠女性,且随妊娠进展降低,但尚不能建议调整剂量,因NAPQI毒性动力学在妊娠期的影响未知。

要点

  • 妊娠女性对乙酰氨基酚稳态平均浓度低于非妊娠女性,随妊娠进展降低。
  • 模拟显示妊娠早期NAPQI摩尔剂量分数最高,但NAPQI体内数据缺乏。
  • 目前尚不能建议妊娠期调整对乙酰氨基酚剂量。

核心结论

  • 妊娠女性对乙酰氨基酚暴露低于非妊娠女性,且与妊娠持续时间相关。
  • 尚不能建议调整剂量,因妊娠对NAPQI毒性动力学的影响未知。

研究设计与样本

  • 建立非妊娠和妊娠女性对乙酰氨基酚及其代谢物的生理药代动力学模型。
  • 考虑妊娠期影响对乙酰氨基酚药代动力学的生理和酶学变化。
  • 使用拟合优度图和与体内药代动力学数据比较评估模型。

主要发现

  • 模型成功预测非妊娠和妊娠女性中对乙酰氨基酚及其代谢物的药代动力学。
  • 每6小时给予1000 mg后,第三妊娠期Css,avg最低,中位数(四分位距)为4.5(3.8-5.1)mg/L。
  • 非妊娠、第一妊娠期和第二妊娠期Css,avg分别为6.7(5.9-7.4)、5.6(4.7-6.3)和4.9(4.1-5.5)mg/L。
  • 假设妊娠期细胞色素P450 2E1活性持续升高,转化为NAPQI的摩尔剂量分数在第一妊娠期最高,为11.0%(9.1-13.4%),第二妊娠期为9.0%(7.5-11.0%),第三妊娠期为8.2%(6.8-10.1%),非妊娠女性为7.7%(6.4-9.4%)。

临床怎么用

  • 临床可参考模型预测的妊娠期对乙酰氨基酚暴露降低趋势,但不应据此调整剂量。
  • 需进一步研究妊娠期谷胱甘肽丰度和NAPQI体内数据以完善模型。

局限性

  • 妊娠对NAPQI毒性动力学的影响未知,限制剂量调整建议。
  • 缺乏妊娠期谷胱甘肽丰度和NAPQI体内数据,需进一步 refine 模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Little is known about acetaminophen (paracetamol) pharmacokinetics during pregnancy. The aim of this study was to develop a physiologically based pharmacokinetic (PBPK) model to predict acetaminophen pharmacokinetics throughout pregnancy. METHODS: PBPK models for acetaminophen and its metabolites were developed in non-pregnant and pregnant women. Physiological and enzymatic changes in pregnant women expected to impact acetaminophen pharmacokinetics were considered. Models were evaluated using goodness-of-fit plots and by comparing predicted pharmacokinetic profiles with in vivo pharmacokinetic data. Predictions were performed to illustrate the average concentration at steady state (Css,avg) values, used as an indicator for efficacy, of acetaminophen achieved following administration of 1000 mg every 6 h. Furthermore, as a measurement of potential hepatotoxicity, the molar dose fraction of acetaminophen converted to N-acetyl-p-benzoquinone imine (NAPQI) was estimated. RESULTS: PBPK models successfully predicted the pharmacokinetics of acetaminophen and its metabolites in non-pregnant and pregnant women. Predictions resulted in the lowest Css,avg in the third trimester (median [interquartile range]: 4.5 [3.8-5.1] mg/L), while Css,avg was 6.7 [5.9-7.4], 5.6 [4.7-6.3], and 4.9 [4.1-5.5] mg/L in non-pregnant, first trimester, and second trimester populations, respectively. Assuming a constant raised cytochrome P450 2E1 activity throughout pregnancy, the molar dose fraction of acetaminophen converted to NAPQI was highest during the first trimester (median [interquartile range]: 11.0% [9.1-13.4%]), followed by the second (9.0% [7.5-11.0%]) and third trimester (8.2% [6.8-10.1%]), compared with non-pregnant women (7.7% [6.4-9.4%]). CONCLUSION: Acetaminophen exposure is lower in pregnant than in non-pregnant women, and is related to pregnancy duration. Despite these findings, higher dose adjustments cannot be advised yet as it is unknown whether pregnancy affects the toxicodynamics of NAPQI. Information on glutathione abundance during pregnancy and NAPQI in vivo data are required to further refine the presented model.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Mian P, van den Anker JN, van Calsteren K, et al. Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. Clin Pharmacokinet. 2020. PMID: 31347013. doi:10.1007/s40262-019-00799-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。